AVITA Medical, Inc. (RCEL)
10.97
+0.21
(+1.95%)
USD |
NASDAQ |
Sep 03, 16:00
10.95
-0.02
(-0.18%)
After-Hours: 20:00
AVITA Medical Research and Development Expense (Annual) : 20.84M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 20.84M |
| December 31, 2024 | 20.36M |
| December 31, 2023 | 20.82M |
| December 31, 2022 | 13.86M |
| June 30, 2021 | 14.82M |
| June 30, 2020 | 8.461M |
| June 30, 2019 | 10.27M |
| June 30, 2018 | 9.767M |
| June 30, 2017 | 3.539M |
| June 30, 2016 | 2.516M |
| June 30, 2015 | 1.941M |
| June 30, 2014 | 0.7198M |
| Date | Value |
|---|---|
| June 30, 2013 | 2.668M |
| June 30, 2012 | 0.9992M |
| June 30, 2011 | 0.2357M |
| June 30, 2010 | 0.1707M |
| June 30, 2009 | 0.1657M |
| June 30, 2008 | 0.1532M |
| June 30, 2007 | 0.5744M |
| June 30, 2006 | 1.340M |
| June 30, 2005 | 1.171M |
| June 30, 2004 | 0.433M |
| June 30, 2003 | 0.0978M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Halozyme Therapeutics, Inc. | 81.49M |
| Iovance Biotherapeutics, Inc. | 300.27M |
| Editas Medicine, Inc. | 84.68M |
| Arcus Biosciences, Inc. | 523.00M |
| Recursion Pharmaceuticals, Inc. | 425.27M |